Clinical trial • Oncology|Immunology|Haematology

PEGASPARGASE for Acute lymphoblastic leukaemia (ALL)

Clinical trial of PEGASPARGASE for Acute lymphoblastic leukaemia (ALL). open-label. 1636 participants.

Overview

Trial Therapeutic Area
Oncology|Immunology|Haematology
Trial Disease
Acute lymphoblastic leukaemia (ALL)
Drug Modality
Peptide/protein/enzyme
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
19-09-2024
First CTIS Authorization Date
10-10-2024

Trial design

open-label trial in France.

Open Label
Yes
Biomarker Stratified
True, Immunophenotypic characterization: B-lineage vs T-lineage
Target Sample Size
1636

Stratification factors

  • Immunophenotypic characterization (B- or T- lineage)
  • Patient risk group

Eligibility

Recruits 1636 paediatric patients.

Vulnerable Population
Selected vulnerable population: children and adolescents (age > 12 months to < 18 years). Written informed consent obtained before day 8 of treatment.

Inclusion criteria

  • {"criterion_text":"- · Children and adolescents Age > 12 months but < 18 yearsB-lineage or T- lineage ALL"}
  • {"criterion_text":"- · Written informed consent obtained before day 8 of treatment"}

Exclusion criteria

  • {"criterion_text":"- · Ph+/BCR-ABL ALL (ESPhALL protocol)"}
  • {"criterion_text":"- · CNS thrombosis before D12"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- o Adequate asparaginase activity (>100 IU/L) at D33 of induction","definition_or_measurement_approach":"Asparaginase enzymatic activity measured at day 33 of induction; target threshold >100 IU/L."}
  • {"endpoint_text":"- o Toxicity: Incidence of severe toxicities (Grade ≥ 3) directly asparaginaserelated (CNS thrombosis, pancreatitis, anaphylaxia, and hyperbilirubinemia) between D12 and D49 of treatment and anyway before D8 of consolidation","definition_or_measurement_approach":"Incidence of Grade ≥ 3 adverse events judged directly asparaginase-related occurring between day 12 and day 49 of treatment (and before day 8 of consolidation); events include CNS thrombosis, pancreatitis, anaphylaxia, and hyperbilirubinemia."}

Secondary endpoints

  • {"endpoint_text":"- - to evaluate the incidence of rare subgroups of ALL and their prognostic value e.g. so-called “B-other” subgroup: BCR-ABL like (including EBF1-PDGFRB), MEF2D-X, ZNF384-X, TCF3-HLF…","definition_or_measurement_approach":"Assessment of incidence of molecular/cytogenetic rare ALL subgroups and analysis of their prognostic value."}
  • {"endpoint_text":"- - 5 year EFS, DFS and OS of the rare patients with suboptimal response to therapy (induction failure or MRDTP1 ≥ 10-3) and ABL-class fusions ALLs treated with imatinib","definition_or_measurement_approach":"Five-year event-free survival (EFS), disease-free survival (DFS) and overall survival (OS) for specified patient subgroups; measured at 5 years."}
  • {"endpoint_text":"- - Imatinib related adverse events (immediate and long term, cf appendix 9) in the rare patients with suboptimal response to therapy (induction failure or MRDTP1 ≥ 10-3) and ABL-class fusions ALLs treated with imatinib","definition_or_measurement_approach":"Collection and analysis of immediate and long-term adverse events related to imatinib in the specified patient subgroup."}

Recruitment

Planned Sample Size
1636
Recruitment Window Months
105
Consent Approach
Written informed consent obtained before day 8 of treatment.

Geography

Total Number Of Sites
28
Total Number Of Participants
1636

France

Earliest CTIS Part Ii Submission Date
30-09-2024
Latest Decision Or Authorization Date
07-04-2026
Processing Time Days
554
Number Of Sites
28
Number Of Participants
1636

Sites

Site Name
Assistance Publique Hopitaux De Paris
Department Name
Service d’Hémato-Immunologie
Principal Investigator Name
André BARUCHEL
Principal Investigator Email
andre.baruchel@aphp.fr
Contact Person Name
André BARUCHEL
Contact Person Email
andre.baruchel@aphp.fr
Site Name
CHU Limoges / Hôpital de la Mère et de l’Enfant
Department Name
Service d'Hématologie - Oncologie pédiatrique
Principal Investigator Name
PIGUET Christophe
Principal Investigator Email
christophe.piguet@chu-limoges.fr
Contact Person Name
PIGUET Christophe
Site Name
CHU Brest / Hôpital Morvan
Department Name
Département de Pédiatrie et Génétique Médicale CHRU Morvan
Principal Investigator Name
CARAUSU Liana
Principal Investigator Email
liana.carausu@chu-brest.fr
Contact Person Name
CARAUSU Liana
Contact Person Email
liana.carausu@chu-brest.fr
Site Name
CHU Besancon
Department Name
Hématologie Oncologie pédiatrique
Principal Investigator Name
SIMON Pauline
Principal Investigator Email
p1simon@chu-besancon.fr
Contact Person Name
SIMON Pauline
Contact Person Email
p1simon@chu-besancon.fr
Site Name
CHU Dijon Bourgogne Hôpital François Mitterand
Department Name
Service Immuno-Hématologie Oncologie Pédiatrique
Principal Investigator Name
DESPLNATES Claire
Principal Investigator Email
claire.desplantes@chu-dijon.fr
Contact Person Name
DESPLNATES Claire
Contact Person Email
claire.desplantes@chu-dijon.fr
Site Name
CHU CLERMONT FERRAND - Hôpital Estaing,
Department Name
Unité Onco- Hématologie Pédiatrique
Principal Investigator Name
KANOLD Justyne
Principal Investigator Email
jkanold@chu-clermontferrand.fr
Contact Person Name
KANOLD Justyne
Contact Person Email
jkanold@chu-clermontferrand.fr
Site Name
CHU Angers
Department Name
Pôle Femme Mère Enfant ; Unité d’Hématologie/Oncologie pédiatrique
Principal Investigator Name
PELLIER Isabelle
Principal Investigator Email
ispellier@chu-angers.fr
Contact Person Name
PELLIER Isabelle
Contact Person Email
ispellier@chu-angers.fr
Site Name
CHU Bordeaux Haut-Leveque
Department Name
Hôpital de Enfants, Unité Onco-Hématologie Pédiatrique
Principal Investigator Name
DUCASSOU Stéphane
Principal Investigator Email
stephane.ducassou@chu-bordeaux.fr
Contact Person Name
DUCASSOU Stéphane
Site Name
CHU Amiens-Picardie - Site Sud
Department Name
Service d’oncolologie, Hématologie pédiatrique
Principal Investigator Name
LEGLISE Camille
Principal Investigator Email
leglise.camille@chu-amiens.fr
Contact Person Name
LEGLISE Camille
Contact Person Email
leglise.camille@chu-amiens.fr
Site Name
CHU Caen​
Department Name
Unité d'hémato-immuno-oncologie pédiatrique
Principal Investigator Name
BODET Damien
Principal Investigator Email
bodet-d@chu-caen.fr
Contact Person Name
BODET Damien
Contact Person Email
bodet-d@chu-caen.fr
Site Name
CHU Lille Hopital Jeanne de Flandre
Department Name
Unité d'hématologie pédiatrique
Principal Investigator Name
Abou Chahla Wadih
Principal Investigator Email
wadih.abouchahla@chru-lille.fr
Contact Person Name
Abou Chahla Wadih
Contact Person Email
wadih.abouchahla@chru-lille.fr
Site Name
CHU Grenoble Alpes
Department Name
Service onco hématologie pédiatrique
Principal Investigator Name
ARMARI ALLA Corinne
Principal Investigator Email
CArmariAlla@chu-grenoble.fr
Contact Person Name
ARMARI ALLA Corinne
Contact Person Email
CArmariAlla@chu-grenoble.fr
Site Name
CHU Croix Rousse-Lyon
Department Name
Service d'immuno-hématologie pédiatrique et de transplantation de moelle osseuse
Principal Investigator Name
HALFON-DOMENECH Carine
Principal Investigator Email
carine.halfondomenech@ihope.fr
Contact Person Name
HALFON-DOMENECH Carine
Contact Person Email
carine.halfondomenech@ihope.fr
Site Name
CHU de Montpellier
Department Name
UAM Hématologie et Oncologie Pédiatrique
Principal Investigator Name
HAOUY Stéphanie
Principal Investigator Email
s-haouy@chu-montpellier.fr
Contact Person Name
HAOUY Stéphanie
Contact Person Email
s-haouy@chu-montpellier.fr
Site Name
CHU Nantes - HME-Department onco-hematology pédiatric
Department Name
Service d'hématologie et oncologie pédiatriques
Principal Investigator Name
THOMAS Caroline
Principal Investigator Email
caroline.thomas@chu-nantes.fr
Contact Person Name
THOMAS Caroline
Contact Person Email
caroline.thomas@chu-nantes.fr
Site Name
CHU de Nancy – Hôpitaux de Brabois
Department Name
Service d'hémato-oncologie pédiatrique
Principal Investigator Name
LUBNAU Marion
Principal Investigator Email
m.lubnau@chru-nancy.fr
Contact Person Name
LUBNAU Marion
Contact Person Email
m.lubnau@chru-nancy.fr
Site Name
CHU Marseille - Hôpital Nord
Department Name
Service de Pédiatrie et hématologie pédiatrique
Principal Investigator Name
MICHEL Gerard
Principal Investigator Email
gmichel@ap-hm.fr
Contact Person Name
MICHEL Gerard
Contact Person Email
gmichel@ap-hm.fr
Site Name
CHU Saint Etienne Hôpital Nord
Department Name
Pôle mère enfant-Unité Hématologie - Oncologie pédiatrique
Principal Investigator Name
THOUVENIN-DOULET Sandrine
Principal Investigator Email
sandrine.thouvenin@chu-st-etienne.fr
Contact Person Name
THOUVENIN-DOULET Sandrine
Site Name
CHU de Tours - Hôpital Clocheville
Department Name
Service d'Onco-Hématologie Pediatrique
Principal Investigator Name
LEJEUNE Julien
Principal Investigator Email
j.lejeune@chu-tours.fr
Contact Person Name
LEJEUNE Julien
Contact Person Email
j.lejeune@chu-tours.fr
Site Name
Trousseau Hospital
Department Name
Service Hémato-immuno- oncologie
Principal Investigator Name
PETIT Arnaud
Principal Investigator Email
arnaud.petit@trs.aphp.fr
Contact Person Name
PETIT Arnaud
Contact Person Email
arnaud.petit@trs.aphp.fr
Site Name
CHU de Poitiers
Department Name
Service Oncologie-Hématologie pédiatrique
Principal Investigator Name
DUPRAZ Chrystelle
Principal Investigator Email
Chrystelle.dupraz@chu-poitiers.fr
Contact Person Name
DUPRAZ Chrystelle
Site Name
CHU de Nice Archet
Department Name
Service d'hémato-oncologie pédiatrique
Principal Investigator Name
ROHRLICH Pierre Simon
Principal Investigator Email
rohrlich.ps@chu-nice.fr
Contact Person Name
ROHRLICH Pierre Simon
Contact Person Email
rohrlich.ps@chu-nice.fr
Site Name
CHU de Rouen - Hôpital Charles Nicolle
Department Name
Hémato-cancérologie pédiatrique
Principal Investigator Name
SCHNEIDER Pascale
Principal Investigator Email
pascale.schneider@chu-rouen.fr
Contact Person Name
SCHNEIDER Pascale
Contact Person Email
pascale.schneider@chu-rouen.fr
Site Name
Hôpital Saint-Louis
Department Name
Unité Hématologie Adolescents et Jeunes Adultes
Principal Investigator Name
BOISSEL Nicolas
Principal Investigator Email
nicolas.boissel@sls.aphp.fr
Contact Person Name
BOISSEL Nicolas
Contact Person Email
nicolas.boissel@sls.aphp.fr
Site Name
CHU de Rennes
Department Name
Pôle pédiatrieHémato-cancérologie pédiatrique
Principal Investigator Name
GANDEMER Virginie
Principal Investigator Email
virginie.gandemer@chu-rennes.fr
Contact Person Name
GANDEMER Virginie
Site Name
CHU Strasbourg - Hôpital de Hautepierre
Department Name
Service d'Onco-Hématologie Pédiatrique
Principal Investigator Name
PAILLARD Catherine
Principal Investigator Email
catherine.paillard@chru-strasbourg.fr
Contact Person Name
PAILLARD Catherine
Site Name
CHU Toulouse
Department Name
Service Pédiatrie - Hématologie Immunologie Oncologie
Principal Investigator Name
PASQUET Marlène
Principal Investigator Email
pasquet.m@chu-toulouse.fr
Contact Person Name
PASQUET Marlène
Contact Person Email
pasquet.m@chu-toulouse.fr
Site Name
CHU Reims – Hôpital Maison Blanche
Department Name
Service d'Hémato-Oncologie Pédiatrique-
Principal Investigator Name
PLUCHART Claire
Principal Investigator Email
cpluchart@chu-reims.fr
Contact Person Name
PLUCHART Claire
Contact Person Email
cpluchart@chu-reims.fr

Sponsor

Primary sponsor

Full Name
Assistance Publique Hopitaux De Paris
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
PEGASPARGASE
Active Substance
PEGASPARGASE
Modality
Peptide/protein/enzyme
Routes Of Administration
INJECTION
Route
INJECTION
Authorisation Status
Authorised

Related trials

Other published trials that may interest you.